Opportunity timeline

PostedAug 6, 2026
DeadlineOct 1, 2026

In plain English

The Defense Health Agency is seeking quotes from pharmaceutical companies for drugs being considered for the Uniform Formulary. The November 2026 review covers topical atopy treatments and MET exon 14 lung cancer drugs, including Anzupgo, Eucrisa, Opzelura, Vtama, Zoryve, Tabrecta, and Tepmetko. The RFQ is HT9402-26-Q-9401, with a pre-quotation teleconference on August 12, 2026; other deadlines are in the RFQ.

About this opportunity

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary…

Time remaining

Closes Oct 1, 2026

17Days
:
14Hours
:
46Min
:
08Sec

Related Opportunities

Bid details are gathered and summarized automatically. Please verify details at the original source.

Ref No.

BS-E178E2